Last update 01 Nov 2024

Adenomyosis

Last update 01 Nov 2024

Basic Info

Synonyms

ADENOMYOSIS, Adenomyoses, Adenomyosis

+ [44]

Introduction

The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma.

Drugs associated with Adenomyosis

Ulipristal Acetate

Target

Mechanism

PR modulators

Active Org.

Laboratoire HRA Pharma SA [+2]

Originator Org.

HRA Pharma Development SARL

Active Indication

Pregnancy [+1]

Inactive Indication

Abnormal uterine bleeding [+8]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

EU [+3]

First Approval Date15 May 2009

Quinagolide Hydrochloride

Target

D2 receptor

Mechanism

D2 receptor agonists

Active Org.

Originator Org.

Active Indication

Inactive Indication

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date24 Sep 1997

Dienogest

Target

ER x PR

Mechanism

ERs agonists [+1]

Active Org.

Bayer HealthCare Pharmaceuticals, Inc. [+3]

Originator Org.

Bayer HealthCare Pharmaceuticals, Inc.

Active Indication

Dysmenorrhea [+4]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date11 Dec 1991

278

Clinical Trials associated with Adenomyosis

IRCT20170612034489N2 / SuspendedPhase 3IIT

Effect of Melatonin on pelvic pain relief in women with endometriosis

Start Date21 Aug 2639

Sponsor / Collaborator

Islamic Azad University

NCT06652945 / Not yet recruitingNot ApplicableIIT

Efficacy of Uterine Artery Embolization (UAE) in Management of Symptomatic Uterine Adenomyosis

Aim of the work:
Evaluating the efficiency of uterine artery embolization as a minimally invasive method of treatment in management of symptomatic women with uterine adenomyosis

Start Date01 Mar 2025

Sponsor / Collaborator

Assiut University

NCT06663553 / Not yet recruitingNot ApplicableIIT

Protocol for a Comparative Study of the Efficacy of Transumbilical Laparoendoscopic Single-site Surgery (TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Hysterectomy Performed on Patients with Enlarged Uterus: a Prospective Single-blinded, Randomized Clinical Trial

Enlarged uterus is frequently encountered in clinical practice, and its incidence due to conditions such as adenomyosis, uterine fibroids, and other gynecological disorders has steadily increased over the years statistically. For example, greater healthcare awareness has led to more frequent early diagnoses of these conditions, contributing to the observed rise in incidence. Additionally, increasing life expectancy results in more women reaching the perimenopausal and postmenopausal stages, during which conditions like uterine fibroids and adenomyosis become more prevalent. For these women, hysterectomy (removal of the entire uterus) is often the recommended option of treatment.
With advances in surgical techniques over recent decades, there has been a notable shift from traditional open abdominal surgeries to minimally invasive approaches. Laparoscopic surgery has been widely adopted, significantly reducing the size and number of incisions required, thereby promoting faster recovery, minimizing postoperative pain, and reducing the risk of complications.
However, conventional multi-port laparoscopic hysterectomy still presents certain challenges, such as large uterus extraction following resection, and concerns about healing of incisions. In contrast, innovative techniques like Transumbilical Laparoendoscopic Single-Site Surgery(TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery(vNOTES) both take advantage of natural anatomical openings to achieve minimal or no visible scarring. Studies demonstrate that these techniques provide superior outcomes in terms of reduced pain, faster recovery, and quicker return to daily activities compared to traditional multi-port laparoscopic approaches.
Yet a direct comparison of the efficacy of these two methods in real-world, particularly for enlarged uterus, remains inconclusive. Thus this study aims to evaluate and compare the outcomes of these two techniques in patients with enlarged uteri. Participants will be randomly assigned to receive one of the two surgical approaches, ensuring an unbiased comparison of the efficacy of the procedures in terms of healing status and recovery time.

Start Date01 Dec 2024

Sponsor / Collaborator

West China Second University Hospital

100 Clinical Results associated with Adenomyosis

100 Translational Medicine associated with Adenomyosis

0 Patents (Medical) associated with Adenomyosis

4,077

Literatures (Medical) associated with Adenomyosis

01 Jan 2025·Radiology Case Reports

Delayed diagnosis of Herlyn-Werner-Wunderlich syndrome with diffuse adenomyosis in bilateral horns

Article

Author: Silwal, Prabhat ; Paudel, Mukesh ; Sharma, Saroj ; Adhikari, Roshna ; Thapa, Sachchu

The Herlyn-Werner-Wunderlich syndrome is a rare congenital disorder with uterus didelphys, unilateral obstructed hemivagina and ipsilateral renal agenesis, more common on right side. HWW syndrome usually presents at puberty with symptoms like pelvic pain, dysmenorrhea and palpable mass due to the associated hematocolpos or hematometra. Delayed presentation in adulthood as infertility can occur in case of incomplete vaginal septum. Short term complications like pyohematocolpos, pyosalpinx, or pelviperitonitis, and long-term complications, such as endometriosis, increased risk of abortion and infertility can occur. Ultrasound is the initial investigation which demonstrates uterine anomaly, renal agenesis and hematocolpos.Magnetic resonance imaging (MRI) is the imaging modality of choice which helps in confirmation of diagnosis, delineation of vaginal septum, communication between 2 cavities and associated pathologies like adenomyosis better.Vaginal septum resection is the treatment of choice for obstructed hemivagina with hematocolpos. We present you a case of 43 years female with cyclical dysmenorrhea starting few years after menarche with uterine didelphys, left sided vaginal septum with hematocolpos and left renal agenesis. Along with this, diffuse bilateral adenomyosis was present which is uncommonly associated with this anomaly as obstruction is at the level of vagina. Patient was diagnosed late due to misdiagnosis and later treated with septal resection for hematocolpos and with hormonal medications for adenomyosis.

01 Jan 2025·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Aberrant TCF21 upregulation in adenomyosis impairs endometrial decidualization by increasing PDE4C expression

Article

Author: Ouyang, Jing ; Li, Guojing ; Liu, Na ; Xu, Hong ; Wei, Chenxuan ; Yu, Ruoer ; Lin, Yu ; Gu, Nihao

BACKGROUNDImpaired decidualization is a major cause of infertility in patients with adenomyosis (AM). However, the effect of transcription factor 21 (TCF21) on AM and the underlying mechanism of associated-impaired decidualization remain unclear. The aim of this study was to investigate the expression of TCF21 in endometrial tissues of AM patients and the specific mechanisms by which it impairs the decidualization of human endometrial stromal cells (HESCs), with a view to improving the reproductive outcome of AM infertile patients.METHODSWe compared gene expressions via transcriptomics between the control and AM-associated recurrent implantation failure (RIF) groups. qRT-PCR, western blot, and IHC were performed to confirm the expression and location of TCF21 in the endometrium. Furthermore, we confirmed that high expression of TCF21 impairs decidualization by qRT-PCR, immunofluorescence, and western blot. RNA-seq following overexpression of TCF21 in HESCs was conducted to identify TCF21-related molecular changes during in vitro decidualization. Then we performed ChIP-seq/qPCR and dual-luciferase reporter assay to explore the exact interaction between TCF21 and PDE4C. The related downstream mechanisms were further proved using IHC, qRT-PCR, western blot, and ELISA.RESULTSAccording to the RNA-seq analysis, TCF21 expression was remarkably higher in the endometrium of the AM-related RIF group compared to the control group. We confirmed the same results using samples from patients with AM and controls. TCF21 overexpression in HESCs impaired decidualization through suppression of decidual markers and cytoskeleton alterations. The mechanistic analysis revealed that TCF21 inhibited intracellular cAMP levels by directly increasing PDE4C expression and suppressing FOXO1 expression.CONCLUSIONSTCF21 compromises decidualization in patients with AM via the PDE4C/cAMP-FOXO1 axis, which offers valuable insights on the pathology of decidualization-related infertility and indicates a potential treatment to improve endometrial receptivity in AM.

31 Dec 2024·Gynecological Endocrinology

Efficacy and uterine bleeding patterns in initiating goserelin therapy during different menstrual phases in patients with adenomyosis: a prospective cohort study

Article

Author: Sun, Hao ; Yan, Shumin ; Li, Dong ; Ming, Yuan ; Ren, Qianhui ; Wang, Xinyu ; Lin, Ying ; Jiao, Xue ; Wang, Guoyun ; Pan, Zangyu

OBJECTIVEWe carried out this study to explore the possibility of initiating goserelin therapy during the non-menstrual period in patients diagnosed with adenomyosis.METHODS115 premenopausal adenomyosis patients were enrolled and divided into three groups based on their menstrual cycle phase during the initial outpatient visit: menstrual, follicular, and luteal. Each received a 3.6 mg subcutaneous dose of goserelin monthly for three months. The endpoints encompassed alterations in uterine volume, dysmenorrhea Numerical Rating Scale (NRS) score, CA125 level, hemoglobin (HGB) after a 12-week treatment course, and the occurrence and duration of uterine hemorrhage during the first treatment cycle.RESULTSAnalysis revealed that the timing of goserelin therapy initiation in the menstrual cycle did not significantly impact its effectiveness in reducing uterine size, alleviating pain, lowering CA125 levels, or improving hemoglobin concentrations. However, patients starting treatment during the luteal phase experienced increased uterine bleeding (reference: menstrual period, OR = 4.33, 95% CI 1.23-15.25, p = .023).CONCLUSIONSThe results suggested non-inferiority of goserelin therapy initiated during the non-menstrual period, but the uterine bleeding rate was higher in the luteal phase group. Therefore, goserelin treatment for outpatient adenomyosis patients should not be limited to starting during the menstrual period; it can also be initiated outside the menstrual period, providing more convenience for patients as most consultations occur outside the menstrual period. However, the use of goserelin during the luteal phase should be avoided to reduce the risk of exacerbated bleeding, especially in anemic patients with heavy menstrual bleeding. This study highlights the importance of individualizing treatment initiation based on the patient's health profile to optimize therapeutic outcomes and minimize adverse effects.TRIAL REGISTRATIONChiCTR2200059548.

News (Medical) associated with Adenomyosis

06 Mar 2023

·www.prnewswire.com

SIR Foundation Receives Major Gift to Support Research Grants and Panel on Uterine Health

PHOENIX, March 6, 2023 /PRNewswire/ -- The Society of Interventional Radiology (SIR) Foundation announced a major gift from John Lipman, MD, FSIR, of Atlanta, that will propel uterine fibroid research forward. This gift will support four years of funding for SIR Foundation's newly announced Dr. Scott C. Goodwin Uterine Artery Embolization Grant and five years of funding for the Dr. James B. Spies Global Summit on Uterine Fibroid and Adenomyosis Research. The announcement was made at the SIR Foundation Gala on March 5 during the SIR 2023 Annual Scientific Meeting. The Dr. Scott C. Goodwin Uterine Artery Embolization Grant is focused on advancing uterine fibroid and uterine artery embolization research and will launch in October 2023. The first Dr. James B. Spies Global Summit on Uterine Fibroid and Adenomyosis Research will be hosted in June 2023. "Research into uterine fibroids and adenomyosis and the minimally invasive treatments that can address these conditions, such as uterine artery embolization, are invaluable in providing care to women," said SIR Foundation Board Chair Theresa M. Caridi, MD, FSIR. "We are incredibly grateful to Dr. Lipman for his personal commitment to advancing the future of interventional radiology for patients and our colleagues in all practice settings." Scott C. Goodwin, MD, FSIR, and James B. Spies, MD, FSIR, are highly regarded pioneers of uterine fibroid research, having led the SIR Foundation's Fibroid Registry, the largest collection of data on uterine fibroids, and conducted foundational research into uterine artery embolization. Dr. Goodwin and Dr. Spies are long-term members of the SIR, having each served as SIR president, as well as members of SIR Foundation's leadership. Dr. Lipman is a widely recognized expert on uterine fibroids and uterine fibroid embolization (UFE), having performed more than 10,000 UFE treatments throughout his career. Since 2015, he has served as founder and medical director of the Atlanta Fibroid Center, a renowned outpatient medical center treating patients from around Atlanta, the United States and world. In addition to his medical practice, Dr. Lipman is an active public speaker and advocate, delivering regular lectures and making media appearances to ensure more widespread knowledge about uterine fibroids among both medical and general audiences. "Dr. Goodwin and Dr. Spies have had a lasting and transformative impact on research into uterine fibroids and the safe and effective procedure of uterine artery embolization," said Dr. Lipman. "I am inspired by their decades-long service as physicians, researchers, educators and advocates, and grateful to have this opportunity to support ongoing research into this historically underfunded area of care afflicting historically underserved women in particular." About the Society of Interventional Radiology Foundation SIR Foundation fosters research and education in interventional radiology for the purposes of advancing scientific knowledge, increasing the number of skilled investigators in interventional radiology and developing innovative therapies that lead to improved patient care and quality of life. For more than 30 years, SIR Foundation has made grants and conducted research panels, driving research and innovation to build the future of interventional radiology and support promising interventional research. Visit sirfoundation.org. About the Society of Interventional Radiology The Society of Interventional Radiology is a nonprofit, professional medical society representing more than 8,000 practicing interventional radiology physicians, trainees, scientists and clinical associates, dedicated to improving patient care through the limitless potential of image-guided therapies. SIR's members work in a variety of settings and at different professional levels—from medical students and residents to university faculty and private practice physicians. Visit sirweb.org. The Society of Interventional Radiology is holding its Annual Scientific Meeting March 4–9, 2023, at the Phoenix Convention Center. Visit sirmeeting.org. SOURCE Society of Interventional Radiology Foundation

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Adenomyosis

Basic Info

Related

Analysis